Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis

To the Editor: Over the past 3 decades, the routine use of erythropoiesis-stimulating agents (ESA) has enabled the correction of anemia in most patients with end-stage renal disease (ESRD), reducing the need for blood transfusions and improving the quality of life of severely anemic patients.1 Almost all ESA-treated hemodialysis patients receive parenteral iron to ensure sufficient available iron for ESA therapy.1–4 Iron deficiency is common in hemodialysis patients due to inadequate iron mobilization from repleted storage sites (functional iron deficiency) and blood loss related to the hemodialysis procedure itself, to routine blood sampling for laboratory tests (especially for monitoring of uremia), and to occult fecal bleeding due to uremic enteropathy.5,6

Until recently, iron overload was considered to be very rare among hemodialysis patients, but it is now an increasingly recognized clinical problem.7–11 The liver is the main site of iron storage, and the liver iron concentration (LIC) correlates closely with total iron stores in patients with genetic hemochromatosis and hemosiderosis secondary to hematological disorders.12 Magnetic resonance imaging (MRI) is now the gold standard method for LIC estimation in nonrenal patients with iron-overload disorders.12 A recent study of LIC in hemodialysis patients using quantitative MRI, and another study based on magnetic susceptometry a few years ago, demonstrated a strong link between infused iron dose and liver iron load in this setting.7,9

Compared to hemodialysis patients, patients undergoing peritoneal dialysis (PD) have fewer sources of blood loss,5,6,11 and guidelines therefore advocate oral iron as first-line therapy. Furthermore, the ferritin targets recommended in current guidelines are far lower and more physiological in PD than in hemodialysis patients.2–4,13 Thus, almost all hemodialysis patients, but few PD patients, receive parenteral iron. In contrast to the situation regarding hemodialysis patients, there are no published data on liver iron content in PD patients. Moreover, given the major difference in iron therapy between hemodialysis and PD patients, an analysis of this specific population of patients with ESRD may give useful information on the influence of ESRD itself on liver iron load. The aim of this study was therefore to determine LIC in PD patients by MRI.

METHODS

Patients and Dialysis

This observational study was carried out between 17 June 2014 and 17 November 2015. A total of 32 adult patients receiving PD were recruited, and their LICs were analysed by MRI. The patients had been treated for at least 2 months in a PD unit belonging to 1 of 4 nephrology divisions in the Paris region (Hôpital Pitié-Salpêtrière; CHU Bicêtre, Kremlin-Bicêtre; CH Marc Jacquet, Melun; and HP Claude Galien, Quincy-sous-Sénart). The inclusion and exclusion criteria have been described elsewhere.7

All participants gave their written informed consent after receiving a verbal explanation from their nephrologist of the reasons for the extra blood sampling, genetic testing in case of iron overload, and MRI scans. Ethical approval for the study was granted by the Drug, Devices and Clinical Trials Committee of Claude Galien hospital (COMEDIMS Claude Galien, 9 December 2004; in France, COMEDIMS follows the use of drugs and devices in hospitals and has the role of an institutional review board).

The treatment of anemia in these patients was carried out according to usual practice and remained unchanged during the study; it followed European Renal Best Practice (ERBP) guidelines and comprised, if required, ESA, and iron.13 In France, the first step in iron therapy is to advise patients to eat red meat. Oral iron therapy is prescribed only if dietary measures fail or if iron deficiency is substantial. We used i.v. iron only if oral iron was ineffective or poorly tolerated.

Quantitative MRI of Hepatic Iron Stores

A signal-intensity ratio method was used for MRI based on T1 and T2* contrast imaging without gadolinium, as established by Gandon et al. at Rennes University.14 Patients on iron therapy (i.v. or oral) received their iron dose at least 1 week before MRI. The MRI measurements were performed centrally at the Division of Radiology of Claude Galien hospital by the same senior radiologist (Y.C.).
Biological Markers of Iron Metabolism

The efficacy of anemia treatment was determined using a hemoglobin assay and reticulocyte counts every month, as well as monthly or quarterly measurements (depending on local policy) of iron biomarkers (ferritin, transferrin, serum iron, and transferrin saturation (TSAT), soluble transferrin receptors (sTfR), and C-reactive protein). The blood samples for measurement of biological markers of iron metabolism were obtained at least 7 days after the last iron infusion (in patients treated with i.v. iron) or 1 week after the last iron tablet. The closest biological markers of iron metabolism to MRI were analyzed.

Search for C282Y HFE Gene Mutation

PD patients with abnormal iron load on MRI were screened for the C282Y HFE gene mutation (BIOMNIS, Lyon, France; and CERBA, Saint Ouen l’Aumone, France).7

Statistical Analyses

As values did not conform to a Gaussian distribution (Shapiro–Wilks normality test), according to Sheskin, all data are expressed as median and range.15 Prism 6 software (GraphPad, San Diego, CA) was used for all statistical tests.

RESULTS

Study Population

The PD study cohort consisted of 32 French adult patients treated in the Paris region. Twelve other PD patients refused to participate in the study. Demographic, clinical, and biological characteristics of the patients are summarized in Tables 1 and 2. A total of 22 patients received automated PD, whereas the remaining 10 received continuous ambulatory peritoneal dialysis (CAPD) (nurse-assisted CAPD, n = 6; self-CAPD, n = 4). As we had no access to their medical records, before the initiation of dialysis, we were unable to analyze their exposure to therapeutic iron and blood transfusions before ESRD. The oral route was the preferred method of iron administration in these PD patients (8 of 32) (Table 1).

Hepatic Iron Load on MRI

The LIC on MRI was normal (<50 μmol/g) in 26 of 32 patients (Table 1, Figure 1). Iron overload on MRI was mild (50 < LIC < 100 μmol/g) in 5 of 6 PD patients with hemosiderosis (Table 3). Only 1 PD patient had severe iron overload on MRI (> 200 μmol/g) and had received i.v. iron (Table 3). None of the PD patients had moderate iron overload (100 < LIC < 200 μmol/g). Iron overload on MRI was not associated with the C282Y HFE gene mutation (homozygous or heterozygous) in these patients (Table 3).

DISCUSSION

In this study, LIC was measured by MRI in a cohort of 32 adult patients receiving PD. By comparison with 2 cohorts of French patients receiving hemodialysis and studied in 2012 and 2014 by the same centralized radiological method and same radiology team,7,16 we observed striking differences in LIC between our PD patients and the historic hemodialysis cohorts. LIC was normal in most PD patients (26/32: 81.3%) compared to few hemodialysis patients (~16% in the first hemodialysis cohort and 35% in the second hemodialysis cohort (which had a lower ferritin target of anemia treatment)). Only one PD patients treated by peritoneal dialysis and studied by MRI to determine liver iron content.

Table 2. Biochemical markers of iron metabolism in 32 patients treated by peritoneal dialysis and studied by MRI to determine liver iron content

| Variable | Patients treated by peritoneal dialysis (N = 32) |
|----------|-----------------------------------------------|
| Hemoglobin (g/dl) | 11.5 (8.7–16.2) |
| Serum ferritin (μg/l) | 144 (11–885) |
| Serum iron (μmol/l) | 13.2 (5.5–24.3) |
| Serum transferrin (g/l) | 2.3 (1.5–3.6) |
| Transferrin saturation (TSAT) (%) | 23.2 (11–50) |
| Serum transferrin soluble receptors (sTfR) (mg/l) | 3.3 (2.3–7.9) |
| C-reactive protein (mg/l) | 6.7 (1.3–67.6) |

MRI, magnetic resonance imaging. Values shown are median (range).

Table 1. Demographic and clinical characteristics of 32 patients treated by peritoneal dialysis and studied by MRI to determine liver iron content

| Variable | Peritoneal dialysis patients (N = 32) |
|----------|-------------------------------------|
| Age (yr) | 64.5 (34–92) |
| Sex, female (%) | 46.9 |
| Duration of dialysis (mo) | 12.5 (2–52) |
| ESA therapy (%) | 71.9 |
| Darbepoetin dose (µg/mo) | 59.1 (0–150) |
| Iron therapy (i.v. or oral) (%) | 37.5 |
| Parenteral iron therapy (%) | 12.5 |
| Parenteral iron therapy (mg/PD mo) | 0 (0–112.5) |
| Oral iron therapy (%) | 25 |
| Oral iron therapy ingested (mg/PD mo) | 0 (0–2560) |
| Charlson Comorbidity Index | 5 (2–15) |
| Diabetes (%) | 34.4 |
| Normal LIC at MRI (< 50 μmol/g), n | 26 |
| Abnormal LIC at MRI (> 50 μmol/g), n | 6 |
| Mild hepatic iron overload at MRI (51–100 μmol/g), n | 5 |
| Moderate hepatic iron overload (101–200 μmol/g), n | 0 |
| Severe hepatic iron overload (> 200 μmol/g), n | 1 |

LIC, liver iron concentration; MRI, magnetic resonance imaging. Values shown are median (range), percentage (%) of patients, or number (n) of patients.
Patient (3.13%) had severe iron overload, compared to 30.3% of patients in the first hemodialysis cohort and 11.3% of those in the second cohort. We conclude that, in contrast to hemodialysis patients, iron overload on MRI is rare and mostly mild in patients receiving PD.

**Table 3.** Characteristics of 9 peritoneal dialysis patients with either high LIC at MRI or having been treated by i.v. iron

| Patient | Sex | Age at MRI (yr) | LIC at MRI (µmol/g) | Duration of PD before MRI (mo) | Iron (i.v./oral) cumulative dose since initiation of PD (mg) | Duration of iron exposure (d or mo) | Time between iron oral tablet ingestion and MRI (d or mo) | Blood transfusion since initiation of PD (mo) | Serum ferritin (µg/l) | Transferrin saturation (TSAT) (%) | Genetic test HFE |
|---------|-----|----------------|---------------------|------------------------------|-------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------------|--------------------|--------------------------------|------------------|
| 1       | F   | 34             | 230                 | 10                          | i.v. 300 mg                                                 | 3 mo                             | 6 mo                             | 0                                      | 100                | 15                             | Negative         |
| 2       | F   | 75             | 65                  | 21                          | No iron                                                     | 0                                | N/A (no iron therapy)            | 0                                      | 885                | 28                             | Negative         |
| 3       | M   | 63             | 70                  | 14                          | Oral 14,480 mg                                              | 7 mo                             | 8 mo                             | 0                                      | 150                | 35                             | Heterozygous CYS282-Tyr |
| 4       | M   | 78             | 60                  | 28                          | No iron                                                     | 0                                | N/A (no iron therapy)            | 0                                      | 487                | 32                             | Negative         |
| 5       | M   | 73             | 55                  | 3                           | Oral 7880 mg                                                | 3 mo                             | 7 d                              | 0                                      | 124                | 29.9                           | Negative         |
| 6       | M   | 73             | 70                  | 4                           | Oral 3672.5 mg                                              | 4 mo                             | 7 d                              | 0                                      | 159                | 50                             | Negative         |
| 7       | F   | 47             | 20                  | 35                          | i.v. 2000 mg                                                | 2 mo                             | 30.5 mo                          | 0                                      | 111                | 24                             | Not done         |
| 8       | F   | 56             | 5                   | 42                          | i.v. 2000 mg                                                | 21 d                             | 10 mo                            | 0                                      | 201                | 28                             | Not done         |
| 9       | M   | 40             | 5                   | 8                           | i.v. 900 mg                                                 | 8 mo                             | 7 d                              | 0                                      | 57                 | 17                             | Not done         |

F, female; LIC, liver iron concentration; M, male; MRI, magnetic resonance imaging; N/A, not applicable; PD, peritoneal dialysis.
Belkacem Issad¹, Nasredine Ghalii, Séverine Beaudreuil³, Mireille Griuncelli⁵, Yves Cohen⁴ and Guy Rostoker⁵

¹Division of Nephrology and Dialysis, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; ²Division of Nephrology and Dialysis, Centre Hospitalier Marc Jacquet, Melun, France; ³Division of Nephrology, Dialysis and Transplantation, Centre Hospitalier Universitaire Bicêtre, Kremlin-Bicêtre, France; ⁴Division of Radiology, RAMSAY-Générale de Santé, Hôpital Privé Claude Galien, Quincy-sous-Sénart, France; and ⁵Division of Nephrology and Dialysis, RAMSAY-Générale de Santé, Hôpital Privé Claude Galien, Quincy-sous-Sénart, France. E-mail: rostotom@orange.fr

Correspondence: Guy Rostoker, Division of Nephrology and Dialysis, RAMSAY-Générale de Santé, Hôpital Privé Claude Galien, Quincy-sous-Sénart, France. E-mail: rostotom@orange.fr

All the authors declared no competing interests.

ACKNOWLEDGMENTS

Clinical trial registration: International Standard Randomized Controlled Trial Number (ISRCTN): 80100088.

AUTHOR CONTRIBUTIONS

BI contributed to the conception, design, and supervision of the study, data acquisition, and planning and conduct of the study in the peritoneal dialysis unit of the Division of Nephrology and Dialysis, Département d’Urologie et de Néphrologie, Groupe Hospitalier Pitié-Salpêtrière. He also participated in the writing of the article. NG contributed to the study design and data acquisition, and to the planning and conduct of the study in the peritoneal dialysis unit of the Centre Hospitalier Marc Jacquet Division of Nephrology and Dialysis. SB contributed to data acquisition and to the planning and conduct of the study in the peritoneal dialysis unit of the Bicêtre Hospital Division of Nephrology, Dialysis and Transplantation. MG contributed to data acquisition, analysis, and interpretation, and to the statistical analysis, and prepared the tables and figure. YC contributed to the acquisition and analysis of centralized MRI examinations. GR contributed to the conception, design, and supervision of the study, data acquisition, and planning and conduct of the study in the peritoneal dialysis unit of the Hôpital Privé Claude Galien Division of Nephrology and Dialysis. He supervised the statistical analysis, data interpretation, and reporting of the work, and wrote the article.

REFERENCES

1. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18:382–393.
2. KDOQI; National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 suppl 3):S16–S85.
3. Locatelli F, Covic A, Eckardt KU, et al, on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24:348–354.
4. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.
5. Rottembourg J, Rostoker G. Use of intravenous iron supplementation in chronic kidney disease: interests, limits, and recommendations for a better practice. Nephrol Ther. 2015;11:531–542.
6. Macdougall IC, Bircher AJ, Eckardt KU, et al, conference participants. Iron management in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2016;89:28–39.
7. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125:991–999.
8. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89:87–93.
9. Canaveses C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65:1091–1098.
10. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:77–83.
11. Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs. 2016;76:741–757.
12. Barton JC, Edwards CQ, Phatak PD, et al. Handbook of Iron Overload Disorders. New York, NY: Cambridge University Press; 2010.
13. Locatelli F, Bárány P, Covic A, et al, on behalf of the ERA-EDTA ERBP Advisory Board. Kidney Disease. Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346–1359.
14. Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357–362.
15. Sheskin DJ. Handbook of Parametric and Nonparametric Statistical Procedures. 4th ed. Boca Raton, FL: Chapman & Hall, Taylor & Francis Group; 2007.
16. Rostoker G, Griuncelli M, Loridon C, et al. Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis. PLoS One. 2014;9:e115096.

Received 16 January 2017; revised 26 June 2017; accepted 17 July 2017; Published online 22 July 2017

© 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).